Immunosuppressive treatment (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03468972 (ClinicalTrials.gov) | March 2019 | 12/3/2018 | Effect of Immunosuppression in IgA Nephropathy | Effect of Immunosuppression in IgA Nephropathy | Biopsy-proven IgA Nephropathy | Drug: Immunosuppressive treatment;Other: intensive supportive care | Yonsei University | NULL | Not yet recruiting | 19 Years | 75 Years | All | 174 | Phase 4 | Korea, Republic of |
| 2 | NCT03015974 (ClinicalTrials.gov) | January 2016 | 3/1/2017 | Registry of IgA Nephropathy in Chinese Children | Registry of IgA Nephropathy in Chinese Children | IgA Nephropathy;Proteinuria in Nephrotic Range;Immunosuppressive Treatment | Drug: Corticosteroid;Drug: Cyclophosphamide;Drug: Mycophenolate mofetil;Drug: Dipyridamole;Drug: ACE Inhibitor or Angiotensin receptor antagonist | Peking University First Hospital | Nanjing PLA General Hospital;Beijing Children's Hospital;Central South University;The Children's Hospital of Zhejiang University School of Medicine;First Affiliated Hospital, Sun Yat-Sen University;Tongji Hospital;Hunan Children's Hospital;Shanghai Children's Hospital;Nanjing Children's Hospital;Children's Hospital of Chongqing Medical University;Shandong Provincial Hospital;Fuzhou General Hospital;Second Affiliated Hospital of Wenzhou Medical University;Children's Hospital of Hebei Province;Guangzhou Women and Children's Medical Center;Jiangxi Province Children's Hospital;Guangzhou First People's Hospital;Xian Children's Hospital;Capital Institute of Pediatrics, China;First Hospital of Jilin University;Wuhan Women and Children's Medical Center;Tianjin Children's Hospital;Chengdu Women's and Children's Central Hospital;The First People's Hospital of Yunnan | Recruiting | 1 Month | 18 Years | All | 1200 | China | |
| 3 | NCT02523768 (ClinicalTrials.gov) | January 2011 | 4/8/2015 | Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment | Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment | Glomerulonephritis;IgAN | Drug: ATG-F;Drug: Simulect | Centre Hospitalier Universitaire de Saint Etienne | NULL | Active, not recruiting | 18 Years | 75 Years | All | 115 | Phase 4 | France |